Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Basic science

4431 - Analysis of stroma and immune-related gene expression patterns during breast cancer (BC) progression.

Date

10 Sep 2017

Session

Basic science

Presenters

Luciana Molinero

Citation

Annals of Oncology (2017) 28 (suppl_5): v595-v604. 10.1093/annonc/mdx391

Authors

L. Molinero1, J. Albanell2, H. Koeppen3, E. Martinez de Dueñas4, D. Halligan5, A. Guerrero6, J.I. Chacón López-Muñiz7, R. Perez8, S. Antolin9, I. Blancas López-Barajas10, M. Muñoz11, A. Oltra12, M.H. LÓpez de Ceballos13, M. Sánchez-Aragó14, R. Caballero15, E. Carrasco16, A.M. González-Angulo17, A. Lluch18, E.A. Mittendorff17, F. Rojo19

Author affiliations

  • 1 Oncology Biomarker Development, Genentech, Inc., CA 94080 - South San Francisco/US
  • 2 Medical Oncology Department, Hospital del Mar, 8003 - Barcelona/ES
  • 3 Oncology, Genentech, Inc., South San Francisco/US
  • 4 Medical Oncology, Hospital Provincial de Castellón, Castellon/ES
  • 5 Bioinformatics, Fios Genomics, Edinburgh/GB
  • 6 Medical Oncology, Instituto Valenciano de Oncología, Valencia/ES
  • 7 Medical Oncology, Hospital Virgen de la Salud, 45005 - Toledo/ES
  • 8 Medical Oncology, Hospital Universitario Quirón de Madrid, Madrid/ES
  • 9 Clinical Oncology, Complejo Hospitalario U A Coruña, Coruña/ES
  • 10 Medical Oncology, Hospital Clinico San Cecilio, 18150 - Granada/ES
  • 11 Clinical Oncology, H Clinic i Provincial de Barcelona, Barcelona/ES
  • 12 Medical Oncology, Hospital Virgen de los Lirios, Alicante/ES
  • 13 Medical Oncology, HOSPITAL SAN PEDRO DE ALCÁNTARA, 10003 - CÁCERES/ES
  • 14 Traslational Research, GEICAM, 28703 - San Sebastian de los Reyes/ES
  • 15 Traslational Research Director, GEICAM, 28703 - San Sebastian de los Reyes/ES
  • 16 Scientific Director, GEICAM, Madrid/ES
  • 17 Research, The University of Texas MD Anderson Cancer Center, Texas/US
  • 18 Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia/ES
  • 19 Cancer Institute, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
More

Resources

Abstract 4431

Background

Characterization of the immune phenotype of tumors during progression could aid in developing patient-tailored therapy strategies. Here, we sought to identify differences in immune markers comparing paired tumors from primary and metastatic sites from the GEICAM/2009-03 (ConvertHER) study.

Methods

Matched primary and metastases were analyzed by immunohistochemistry as described by Herbst et al., 2014 for PDL1 expression. The nanostring gene expression platform was used to profile and identify differences in the expression of 805 immune-related genes. Significant features (p-value

Results

Out of 44 pairs analyzed for PDL1, 29 (65%) were ER+/HER2-, 3 (7%) ER-/HER2+, 6 (14%) ER+/HER2+ and 6 (14%) ER-/HER2- (TN). PDL1 expression (³1%) was observed in the immune cell (IC) compartment in 11 (19%) ER+/HER2-, 4 (33%) ER+/HER2+, 2 (33%) ER-/HER2+ and 11 (92%) TN samples. No significant differences were observed between primary and metastases. Out of 60 pairs analyzed by nanostring, the most, (40; 67%) were ER+/HER2-, 5 (8%) ER-/HER2+, 7 (12%) ER+/HER2+ and 8 (13%) TN. In the global population, we found that 102 genes were differentially expressed (fold-change >2) between primaries and metastasis. For the ER+/HER2- subgroup, expression of 98 genes significantly differs in metastasis compare to primaries. No clear changes in pre-specified immune signatures were observed, probably due to the high tumor heterogeneity, different treatments and small sample size. Interestingly, analyses of pre-specified gene signatures suggest that metastases have decreased Notch pathway, innate inflammation and TGFb-activated fibroblasts signatures. Moreover, GO-enriched signature analyses suggest that B cell differentiation and type 1 IFN pathway are also reduced in metastases both in the global population and in ER+/HER2- tumors, thus suggesting a decreased immune defense during progression.

Conclusions

Our analysis failed to identify novel immune biomarkers of BC metastases. However, these data pointed out that tumors could relax the immune system response during progression.

Clinical trial identification

NCT01377363.

Legal entity responsible for the study

GEICAM Spanish Breast Group.

Funding

Genentech Inc.

Disclosure

L. Molinero, H. Koeppen: Employee of Genentech. All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.